Pre-clinical data on anti-TNF-α, anti-VEGF and IL-6R blockers as TB HDT in TB animal models and case studies of severe pulmonary TB patients have been encouraging (Okada et al., 2011; Datta et al., 2015). Here, VEGFA is linked to tuberculosis.